Xencor, Inc.

XNCRNASDAQ • USD
12.45 USD
↘ 0.37 (2.85%)AT CLOSE (11:59 AM EDT)
12.50
↘ 0.01 (0.04%)
POST MARKET (AS OF 04:04 PM EDT)
Post Market
AS OF 04:04 PM EDT
12.50
↘ 0.01 (0.04%)
🟢Market: OPEN
Open?$12.79
High?$18.56
Low?$12.10
Prev. Close?$12.81
Volume?732.8K
Avg. Volume?933.9K
VWAP?$12.72
Rel. Volume?0.78x
Bid / Ask
Bid?$12.49 × 100
Ask?$12.51 × 100
Spread?$0.02
Midpoint?$12.50
Valuation & Ratios
Market Cap?939.5M
Shares Out?73.3M
Float?71.5M
Float %?97.6%
P/E Ratio?N/A
P/B Ratio?1.48
EPS?-$1.25
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?6.25Strong
Quick Ratio?6.25Strong
Cash Ratio?0.56Adequate
Debt/Equity?0.19Low
ValuationFAIRLY VALUED
Score
67/100
P/E?
N/A▾
P/B?
1.48CHEAP▾
P/S?
7.48HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
-6.0CHEAP▾
EV/Sales?
8.00HIGH▾
Returns & Efficiency
ROE?
-14.5%WEAK▾
ROA?
-10.5%WEAK▾
Cash Flow & Enterprise
FCF?$-138267000
Enterprise Value?$1.0B
Related Companies
Loading...
News
Profile
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
Employees
260
Market Cap
939.5M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.xencor.com
Listed
2013-12-03
Address
465 N. HALSTEAD ST.
PASADENA, CA 91107
Phone: 626-305-5900
MarketsMoversWatchlist